caa a22 4500 469119535 CHVBK 20180323133134.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF02247430 doi (NATIONALLICENCE)springer-10.1007/BF02247430 Nasal nicotine spray: a rapid nicotine delivery system [Elektronische Daten] [G. Sutherland, M. Russell, J. Stapleton, C. Feyerabend, O. Ferno] Plasma nicotine concentrations following administration by two types of nasal nicotine spray were compared in ten subjects. Absorption was particularly rapid during the first 2.5 min, the average rise in blood nicotine concentrations during this time being 8.6 ng/ml for the two products, followed by a small further rise to an average peak increase of 10.5 ng/ml 5 min after the dose of 2 mg nicotine base (mean 27.8 µg/kg). Despite a four-fold Cmax variation between subjects, the levels of individual subjects were fairly consistent across the two products. There were no significant differences between the two products in blood nicotine concentrations or cardiovascular responses, and the correlation between the AUCs from the two products was 0.68 (P=0.01). Eight subjects reported subjective feelings of light-headedness or slight dizziness, which are not typical after slower absorption from nicotine gum or skin patches. Blood nicotine levels within the smoking range were soon built up with repeated doses, even in the subject with the least efficient nasal absorption. In a second study of ad libitum use under clinical conditions both products appeared sufficiently acceptable for therapeutic use as an aid to smoking cessation. There was no tendency to escalate to excessive use over 4 weeks, and blood nicotine concentrations in nine subjects averaged only 44% of their prior smoking levels. Only one subject had levels equivalent to prior smoking and possible reasons why this was not more common are discussed. Springer-Verlag, 1992 Cigarette smoking nationallicence Nasal nicotine spray nationallicence Nicotine pharmacokinetics nationallicence Nicotine effects nationallicence Nicotine replacement treatment nationallicence Sutherland G. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut Russell M. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut Stapleton J. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut Feyerabend C. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut Ferno O. S:t Clemensgaten 14, S-25234, Helsingborg, Sweden aut Psychopharmacology Springer-Verlag 108/4(1992-09-01), 512-518 0033-3158 108:4<512 1992 108 213 https://doi.org/10.1007/BF02247430 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02247430 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sutherland G. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut NATIONALLICENCE 700 1- Russell M. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut NATIONALLICENCE 700 1- Stapleton J. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut NATIONALLICENCE 700 1- Feyerabend C. Institute of Psychiatry, ICRF Health Behaviour Unit, SE5 8AF, London, UK aut NATIONALLICENCE 700 1- Ferno O. S:t Clemensgaten 14, S-25234, Helsingborg, Sweden aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 108/4(1992-09-01), 512-518 0033-3158 108:4<512 1992 108 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer